Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Vistagen Therapeutics (VTGN) over the last 7 years, with Q4 2025 value amounting to $135000.0.

  • Vistagen Therapeutics' Amortizatization of Intangibles rose 1065.57% to $135000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $522000.0, marking a year-over-year increase of 1035.94%. This contributed to the annual value of $485000.0 for FY2025, which is 997.73% up from last year.
  • As of Q4 2025, Vistagen Therapeutics' Amortizatization of Intangibles stood at $135000.0, which was up 1065.57% from $132000.0 recorded in Q3 2025.
  • Vistagen Therapeutics' Amortizatization of Intangibles' 5-year high stood at $272300.0 during Q4 2021, with a 5-year trough of $92500.0 in Q1 2021.
  • For the 5-year period, Vistagen Therapeutics' Amortizatization of Intangibles averaged around $123420.0, with its median value being $113000.0 (2023).
  • In the last 5 years, Vistagen Therapeutics' Amortizatization of Intangibles skyrocketed by 815151.52% in 2021 and then tumbled by 6268.82% in 2022.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Amortizatization of Intangibles stood at $272300.0 in 2021, then tumbled by 62.69% to $101600.0 in 2022, then increased by 10.24% to $112000.0 in 2023, then grew by 8.93% to $122000.0 in 2024, then increased by 10.66% to $135000.0 in 2025.
  • Its Amortizatization of Intangibles was $135000.0 in Q4 2025, compared to $132000.0 in Q3 2025 and $129000.0 in Q2 2025.